Stocks

Amgen Stock Nears 52-Week High on Raised 2026 Guidance

Guavy AI Editorial Team Published September 4, 2026

Instruments

AMGN

Amgen stock is trading near its 52-week high as guidance for 2026 rises. As of September 3, 2026, shares in Amgen (ISIN US0311621009) are priced at around USD 441.56 on the Nasdaq exchange.

This is just USD 5.47 below the company's recorded 52-week high of USD 447.03. The strong recovery from the lower end of its price range over the past year highlights Amgen's resilience in a competitive market.

The biotech giant has reported revenue growth of around 9 percent in Q2 2026, reaching approximately USD 10.05 billion compared to the same quarter last year. This broad-based expansion across key therapeutic areas is expected to continue.

Amgen has raised its full-year 2026 revenue guidance to a range of USD 38.2 billion to USD 39.4 billion, up from a previous expectation of USD 37.1 billion to USD 38.5 billion.

Amgen Stock Nears 52-Week High on Raised 2026 Guidance

Repatha Shows Significant Benefits in Reducing Cardiovascular Risks and Mortality Rates

Trump's Irish Golf Visit Adds Complexity to County Clare Court Proceedings

Amgen's Repatha Cuts Mortality by 20% in High-Risk Cardiovascular Patients